SCHEMBL6617115

SCHEMBL6617115

Cc1cccc(NC(=O)C(C)(C)C)c1SCc1ccc2c(c1)OCO2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 3/20 0.49
▸ ALDH1A1 P00352 3/20 0.49
▸ HTT P42858 1/20 0.49
▸ ALOX12 P18054 3/20 0.48
▸ HPGD P15428 2/20 0.48
▸ KMT2A Q03164 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ RAB9A P51151 3/20 0.44
▸ NPC1 O15118 2/20 0.44
▸ LMNA P02545 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.42
▸ P2RX7 Q99572 1/20 0.42
▸ MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6617845 0.90 ALDH1A1 (0.46) GAAALDH1A1HTTALOX12HPGD
SCHEMBL6617886 0.84 CA12 (0.43) GAAALDH1A1HTTKMT2AMEN1
SCHEMBL6621607 0.84 KMT2A (0.51) GAAALDH1A1ALOX12HPGDKMT2A
SCHEMBL6618056 0.76 LMNA (0.42) GAAALDH1A1HTTKMT2AMEN1
SCHEMBL6241284 0.76 KMT2A (0.58) ALDH1A1ALOX12HPGDKMT2AMEN1
SCHEMBL6617487 0.76 CYP1A2 (0.41) ALDH1A1ALOX12KMT2AMEN1RAB9A
SCHEMBL6621943 0.74 KMT2A (0.47) GAAALDH1A1ALOX12HPGDKMT2A
SCHEMBL6620820 0.72 KMT2A (0.49) GAAALDH1A1HTTALOX12HPGD
SCHEMBL1709314 0.69 SMN1; SMN2 (0.68) GAAALDH1A1HPGDKMT2AMEN1
SCHEMBL6619330 0.68 CETP (0.49) KMT2AMEN1RAB9ANPC1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6828446-B2 Sulfides such as N-(2-(((6- chloro-1,3-benzodioxol-5-yl)methyl )thio)phenyl)thiophene-2-carboxamide used for controlling metabolism of lipids and prophylaxis of diabetes, Alzheimers disease, atherosclerosis, dyslipidemia and genetic disorders PHARMACIA CORPORATION 2004-12-07 — — US claimed
EP-1463726-A2 AROMATIC THIOETHER LIVER X-RECEPTOR MODULATORS Pharmacia Corporation (US) 2004-10-06 — — EP claimed
US-20030207898-A1 Aromatic thioether liver X-receptor modulators PHARMACIA CORPORATION 2003-11-06 — — US claimed
WO-2003059874-A2 AROMATIC THIOETHER LIVER X-RECEPTOR MODULATORS PHARMACIA CORPORATION (US) 2003-07-24 — — WO claimed
US-6828446-B2 Sulfides such as N-(2-(((6- chloro-1,3-benzodioxol-5-yl)methyl )thio)phenyl)thiophene-2-carboxamide used for controlling metabolism of lipids and prophylaxis of diabetes, Alzheimers disease, atherosclerosis, dyslipidemia and genetic disorders PHARMACIA CORPORATION 2004-12-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207898-A1 Aromatic thioether liver X-receptor modulators NR1H2, NR1H3, NR1H4 GAA 2715/4885ALDH1A1 981/4885HTT 3945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback